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To the Editor:
We congratulate Furck and col-
leagues1 for their excellent analysis of
outcomes after the Norwood operation
in patients with hypoplastic left heart
syndrome, as described in their recent
publication. However, we are con-
cerned that the authors have reported
the rate ofmortality using a nonstandard
strategy for this type of reporting. Furck
and colleagues reported a 30-day mor-
tality of 2.5% for the last 3 years.
They stated that ‘‘Death after this period
and until the subsequent palliative sur-
gery, regardless of whether in or out of
the hospital, was defined as interstage
mortality.’’ They reported interstage
mortality of 15%. This manner of
reporting of outcomes is not consistent
with standardized reporting strategies.
It can be potentially misleading and
can create unrealistic expectations
among referring physicians, caregivers,
and families.
Collaborative international efforts
have resulted in the establishment of
standardized methodologies for the
reporting of mortality and morbidity
associated with pediatric and congen-
ital cardiac surgery.2,3 Operative
mortality is defined as any death, re-
gardless of cause, occurring (1) within
30 days after surgical intervention in
or out of the hospital and (2) after 30
days during the same hospitalization
subsequent to the operation. Thus op-
erative mortality includes all deaths726 The Journal of Thoracic and Cthat occur during the initial hospitali-
zation. Logically, interstage mortality
encompasses all deaths that occur after
the period of time included in opera-
tive mortality but before the stage 2
operation. Thus all mortality during
the initial hospitalization should be
classified as operative mortality and
not interstage mortality.
The most recent analysis of the
Society of Thoracic Surgeons Congen-
ital Heart Surgery Database documents
discharge mortality of 18.7% (447/
2395 patients) after the Norwood (stage
I) operation.4 By reporting only 30-day
mortality and classifying deaths that oc-
cur after 30 days but during the initial
hospitalization as interstage mortality,
the authors have used a methodology
not consistent with standardized meth-
odologies of outcome reporting. If an
author wishes to explore other means
of presentation, one would assume
that it would be done with a degree of
emphasis that was not apparent in this
article. We believe that the use of stan-
dard reporting strategies for mortality is
crucial when reporting the outcomes
after pediatric and congenital cardiac
surgery.
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We thank Jonas and his colleagues
for their interest in our study and for
drawing our attention to the definition
of operative mortality.1
During the review process of the
manuscript, we offered to recalculate
our data on mortality of the Nor-
wood operation according to the def-
inition of The Society of Thoracic
Surgeons Congenital Database Task-
force and the Joint EACTS–STS
Congenital Database Committee,2
but as we gave data on both 30-day
mortality and interstage mortality,
we were allowed to leave the data
as presented.
However, we agree with Jonas and
colleagues that the way of reporting
operative mortality should be consis-
tent to simplify comparison between
groups. We, therefore, recalculated0
FIGURE 1. Operative mortality after the Norwood procedure. Exponentially weighted moving aver-
age (EWMA) with 95% confidence intervals.
Letters to the Editoroperative mortality adhering to the
proposed definition and report that
new information here:
Operative mortality of the Norwood
procedure for hypoplastic left heart
syndrome (death within 30 days after
surgery in or out of the hospital and af-
ter 30 days during the same hospitali-
zation subsequent to the operation)
decreased from 21.1% during the first
3 years to 4.9% during the last 3 years
of the reported 12-year period. Ac-
cordingly, the exponentially weighted
moving average of operative mortality
after the 157 Norwood procedures fell
to 3.58% (Figure 1).
Interstage mortality, accordantly
defined as all deaths that occurred af-
ter the 30-day period or after discharge
from hospital after the Norwood oper-
ation but before the subsequent hemi-
Fontan operation, could be reduced
with introduction of our home surveil-
lance program from 13.2% to 0%.
As recalculations changed our data
only minimally, we hope that the
readers appreciate that we did not try
to mislead anyone or to create unrealis-
tic expectations among referring physi-
cians, caregivers, and families but
rather honestly presented our institu-
tional experience with the Norwood
operation for children with hypoplastic
left heart syndrome.
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THE RADIAL ARTERYAND
RIGHT INTERNAL THORACIC
ARTERY OR SAPHENOUS VEIN
BEYOND 5 YEARS: RESULTS
FROM THE RADIAL ARTERY
PATENCYAND CLINICAL
OUTCOMES TRIAL
To the Editor:
A recent article byHayward and col-
leagues1 presents important data re-
garding the long-term patency and
clinical outcome of the radial artery
(RA), right internal thoracic artery
(ITA), and saphenous vein (SV) when
used as conduits in patients undergoingof Thoracic and Cardiovascular Surgecoronary artery bypass grafting. The
main purpose of the authors’ trial was
to identify the place of the RA in the
hierarchy of options available to sup-
plement the ITA to the left anterior
descending coronary artery. Patients
were monitored at defined time points
(mean, 5.5 years), with the results lead-
ing the authors to suggest that the RA
or free ITA are equally satisfactory in
younger patients and that RA and SV
grafts produce similar angiographic
outcomes in older patients.
Two points are of particular interest.
First, the authors found a striking in-
crease in vein graft patency compared
with that seen in previously published
studies. Second, the authors recognize
the importance of atraumatic harvest-
ing of both the RA and SV in achieving
improved graft performance. These re-
sults were presented at the 2008 Amer-
ican Association for Thoracic Surgery
Meeting, where some relevant points
were raised. In particular, the authors
were asked whether any of the veins
in the study were harvested endoscopi-
cally. The response was that they were
not because endothelial integrity might
have been affected by thismethod, add-
ing ‘‘These veins were all taken in
a shamelessly open no-touch manner.’’
It is not clear which no-touch
method was used, but if it was the
same or similar to that used routinely
in our unit in O¨rebro, the SV would
have been removed without distension
and with its surrounding cushion of
tissue intact.2 This method provides
a graft with a patency rate comparable
with that of the ITA3 and preserves
normal vessel structure that is very
different in appearance from that of
SV grafts prepared conventionally
(Figure 1). We believe that the vasa
vasorum plays an important role in
the improved patency of SVs har-
vested with surrounding tissue be-
cause medial blood flow is restored
through this network of nutrient
microvessels after completion of graft
insertion and removal of vascular
clamps. This does not occur in conven-
tionally harvested veins in which thery c Volume 140, Number 3 727
